Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Oncology

• Publication date

  2000-08-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2000.18.16.2938PMID 10944126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

  1998cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

  1998cited by this paper
• Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

  1998cited by this paper
• Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.

  1997cited by this paper
• Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers

  1997cited by this paper
• Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

  1997cited by this paper
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

  1997cited by this paper
• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  1997cited by this paper
• Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.

  1996cited by this paper
• Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.

  1996cited by this paper
• Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.

  1996cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996cited by this paper
• Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer

  1994cited by this paper
• Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

  1994cited by this paper
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

  1993cited by this paper
• A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.

  1993cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

  1992cited by this paper
• Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).

  1991cited by this paper
• Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.

  1989cited by this paper
• Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

  1989cited by this paper
• Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.

  1988cited by this paper
• Statistical tables for the design of clinical trials

  1987cited by this paper
• Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.

  1987cited by this paper
• One-sample multiple testing procedure for phase II clinical trials.

  1982cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Association between bevacizumab administration and delayed wound healing complications before and after central venous port placement in patients with colorectal cancer.

  2026cites this paper
• Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

  2026cites this paper
• Association between oxaliplatin infusion timing and outcomes with first-line XELOX in colorectal cancer: a retrospective cohort study

  2026cites this paper
• Cosynllm: predicting drug combination synergy with LLM-generated descriptions.

  2026cites this paper
• Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial–the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial

  2026cites this paper
• Prognostic and safety analysis of capecitabine monotherapy versus CapeOx (capecitabine plus oxaliplatin) in elderly patients with high-risk stage II and stage III MRD-negative colorectal cancer

  2025cites this paper
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

  2025cites this paper
• [Translated article] Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer.

  2025cites this paper
• Digestive cancers: mechanisms, therapeutics and management

  2025cites this paper
• Novel exosome-associated LncRNA model predicts colorectal cancer prognosis and drug response

  2025cites this paper
• Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study

  2025cites this paper
• Effect of PEGylated Liposomalization of Oxaliplatin on the Gut Microbiota in Mice.

  2025cites this paper
• Oxaliplatin chemistry: Anticancer platinum-based complex of third-generation oxaliplatin (Eloxatin)

  2025cites this paper
• Targeting the ZMYM2–ANXA9 Axis: Organoid Models Illuminate a Novel Pathway to Overcome Oxaliplatin Resistance in Colorectal Cancer

  2025cites this paper
• A Systematic Review of Disappearing Colorectal Liver Metastases: Resection or No Resection?

  2025cites this paper
• Gallium(III) Complex Induces Immunogenic Cell Death Hallmarks for Chemoimmunotherapy.

  2025cites this paper
• CAPOX vs. FOLFOX for Colorectal Cancer—Real World Outcomes in Ontario, Canada

  2025cites this paper
• In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial

  2025cites this paper
• A machine learning-based prognostic stratification of locoregional interventional therapies for patients with colorectal cancer liver metastases: a real-world study

  2025cites this paper
• Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real‐World Evidence From Regorafenib and Trifluridine/Tipiracil Use

  2025cites this paper
• Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis

  2025cites this paper
• Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers.

  2025cites this paper
• A Normal Metabolizer of DPYD (Dihydropyrimidine Dehydrogenase) Variant c.2194G>A detected in a Patient with Severe Toxicities induced by Fluoropyrimidine-based Regimens: A First Case Report from Bihar, India

  2025cites this paper
• CD47-targeted liposomal chemotherapy upregulates CD47 expression and induces microsatellite instability which enhances cancer immunotherapy.

  2025cites this paper
• Burden of Colorectal Cancer in Northeastern Iran in 2019: A Cross-Sectional Study

  2025cites this paper
• Causes and consequences of RNA:protein cross-links – lessons from chemotherapy

  2025cites this paper
• Systemic chemotherapy for colorectal cancer: a narrative review

  2025cites this paper
• Folate‐Associated Gene Expression in Primary Tumors Is Associated With Tumor Response and Progression‐Free Survival of Patients With Metastatic Colorectal Cancer Undergoing 5‐FU/Leucovorin‐Based Combination Chemotherapy

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs

  2025cites this paper
• LA-ICP-TOFMS Imaging Reveals Significant Influence of Cancer Cell Resistance on Oxaliplatin Compartmentalization in the Tumor Microenvironment

  2025cites this paper
• The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer

  2025cites this paper
• Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015

  2025cites this paper
• Sustainability-based comparative stability of oxaliplatin plus leucovorin and 5-fluorouracil in infusion bags with application to plasma and colonic media samples

  2025cites this paper
• Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach

  2025cites this paper
• Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell

  2025cites this paper
• Developments in the roll-out and performance of CRC screening in Europe.

  2025cites this paper
• Antibody treatments for digestive cancers: Past, present, and future.

  2025cites this paper
• Probiotic bacteria combined with curcumin-loaded chitosan nanoparticles as a promising anti-colorectal cancer agent

  2025cites this paper
• Estimating the Survival Impact of Curative-Intent Liver Therapies for Colorectal Cancer Liver Metastases

  2025cites this paper
• Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review

  2025cites this paper
• Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase 1 Clinical Trial.

  2025cites this paper
• CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate

  2025cites this paper
• Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal Cancer

  2025cites this paper
• Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review

  2025cites this paper
• Review of Options to Traditional HIPEC for Prevention and Treatment of Peritoneal Metastases

  2024cites this paper
• Broussoflavonol F exhibited anti-proliferative and anti-angiogenesis effects in colon cancer via modulation of the HER2-RAS-MEK-ERK pathway.

  2024cites this paper
• Decursin Induces G1 Cell Cycle Arrest and Apoptosis through Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress in Human Colorectal Cancer Cells in In Vitro and Xenograft Models

  2024cites this paper
• Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.

  2024cites this paper
• More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients

  2024influential citation
• Invited Editorial About: “Impact of Tumoral β2-Adrenergic Receptor Expression on Chemotherapeutic Response and Prognosis in Patients with Advanced Colorectal Cancer,” by C. Komine et al.

  2024cites this paper
• Factors Influencing the Duration of Maintenance Therapy in Metastatic Colorectal Cancer

  2024cites this paper
• Combination with oxaliplatin improves abscopal effect of oncolytic virotherapy through reorganization of intratumoral macrophages

  2024cites this paper
• Lymph node ratio prognosticates overall survival in patients with stage IV colorectal cancer

  2024cites this paper
• Sweeten the pill: Multi-faceted polysaccharide-based carriers for colorectal cancer treatment.

  2024cites this paper
• An RNA damage response network mediates the lethality of 5-FU in colorectal cancer

  2024cites this paper
• Expert consensus on the optimal management of BRAFV600E ‐mutant metastatic colorectal cancer in the Asia‐Pacific region

  2024cites this paper
• Journey through the Decades: The Evolution in Treatment and Shared Decision Making for Locally Advanced Rectal Cancer

  2024cites this paper
• MAPK Signaling‐Mediated RFNG Phosphorylation and Nuclear Translocation Restrain Oxaliplatin‐Induced Apoptosis and Ferroptosis

  2024cites this paper
• Ferroptosis-related oxaliplatin resistance in multiple cancers: Potential roles and therapeutic Implications

  2024cites this paper
• Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells.

  2024cites this paper
• Is it Time to Forget the 5-Fluorouracil Bolus?

  2024cites this paper
• Systemic Therapy for Metastatic Colon Cancer: New Frontiers

  2024cites this paper
• Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study

  2024cites this paper
• Evolving patterns of metastatic spread, treatment, and outcome for patients with oligometastatic colorectal cancer

  2024cites this paper
• Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review

  2024cites this paper
• Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1.

  2024cites this paper
• Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

  2024cites this paper
• Managing Chemotherapy-Induced Diarrhea: Efficacy of Interventions for Cancer Patients

  2024cites this paper
• The effect of lifestyle interventions on sarcopenia in advanced colorectal cancer: A systematic review.

  2024cites this paper
• Plasma proteome profiling reveals biomarkers of chemotherapy resistance in patients with advanced colorectal cancer

  2024cites this paper
• Therapeutic Application of Dendrobium fimbriatum Hook for Retinopathy Caused by Ultraviolet Radiation and Chemotherapy Using ARPE-19 Cells and Mouse Retina

  2024cites this paper
• Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20

  2024cites this paper
• Illness trajectories of incurable solid cancers

  2024cites this paper
• Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer.

  2024cites this paper
• Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

  2024cites this paper
• Emerging therapeutic approaches for peritoneal metastases from gastrointestinal cancers

  2024cites this paper
• Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II–III colon cancer: a meta-analysis

  2024cites this paper
• Metastatic colorectal cancer- third line therapy and beyond

  2024cites this paper
• Incidence, Severity and Clinical Correlation of Oxaliplatin Induced Neuropathy in Patients with Colorectal Cancer: A Single Institutional Experience

  2024cites this paper
• Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca4Mn(DPDP)5, MnDPDP and DPDP

  2024cites this paper
• A case of metastatic melanoma in the liver mimicking colorectal cancer with synchronous liver metastasis.

  2024cites this paper
• Oxaliplatin-induced Acute Neurotoxicity Recovers Between Repeat Infusion Cycles: An Axonal Excitability Repeated Multiple Measurements Study.

  2024cites this paper
• Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy

  2024cites this paper
• Integration of mult-omics and nucleotide metabolism reprogramming signature analysis reveals gastric cancer immunological and prognostic features

  2024cites this paper
• Synthesis, Characterizations, and Anticancer Properties of Bifunctional System Based on Gold(I) Alkynyl and Antipyrine

  2024cites this paper
• HMGB1 as an extracellular pro-inflammatory cytokine: Implications for drug-induced organic damage

  2024cites this paper
• Third-Line Treatment and Beyond in Metastatic Colorectal Cancer: What Do We Have and What Can We Expect?

  2024cites this paper
• DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients

  2024cites this paper
• Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer

  2023cites this paper
• The use of adjuvant chemotherapy is not associated with recurrence or cancer-specific death following curative resection for stage III rectal cancer: a competing risks analysis

  2023cites this paper
• Gemcitabine-loaded synthetic high-density lipoprotein preferentially eradicates hepatic monocyte-derived macrophages in mouse liver with colorectal cancer metastases

  2023cites this paper
• Multi‐omic analysis in normal colon organoids highlights MSH4 as a novel marker of defective mismatch repair in Lynch syndrome and microsatellite instability

  2023cites this paper
• Multiple Protein Biomarkers and Different Treatment Strategies for Colorectal Carcinoma: A Comprehensive Prospective.

  2023cites this paper
• Assessment of the Influence of 5-Fluorouracil on SMAD4 and TGFB1 Gene Expression, Apoptosis Induction and DNA Damage in Human Cell Lines

  2023cites this paper
• Surgery of Colorectal Liver Metastases Involving the Inferior Vena Cava: A Systematic Review

  2023cites this paper
• Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers.

  2023cites this paper
• Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer

  2023cites this paper
• An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types

  2023cites this paper
• Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review

  2023cites this paper